Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company.

Medtronic noted that the system's "treat to target" approach and the option to set glucose targets as low as 100mg/dL enable it to mimic non-diabetic glucose levels closely. Its real-world data ...